Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCSK9 Inhibitor for Early Neurological Deterioration in Acute Ischemic Stroke with Coronary Heart Disease
ChiCTR2300078198Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of evolocumab in ischemic stroke, coronary arteriosclerosis and atherosclerotic disease (2 arms), sponsored by The First Affiliated Hospital of Dalian Medical University. Primary endpoint: Incidence of early neurological deterioration within 7 days. Started Dec 2023; status: recruiting.
02
Drugs
evolocumab
03
Conditions
ischemic strokecoronary arteriosclerosisatherosclerotic disease
Beyond the preview
Go deeper on ChiCTR2300078198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078198.